The Next 18 Months of Weight Loss Medicine: What Is Coming After Ozempic

Ozempic was the opening act. Wegovy made it mainstream. Zepbound raised the bar. But what most people do not realize is that the medications available today represent generation one and generation two of a revolution that is still accelerating.

In the next 18 months, at least four new weight loss medications are expected to reach the market or enter late-stage regulatory review — each with a different mechanism, a different delivery method, or a different level of efficacy.

This guide walks through every major medication in the pipeline, what makes each one different, and what it means for your decision right now.

What Is Available Today

Semaglutide (Wegovy / Ozempic) is a single GLP-1 receptor agonist. It reduces appetite by mimicking the hormone your gut releases after eating. Clinical trials show approximately 15 percent average body weight loss over 68 weeks. FDA-approved, widely available, covered by a growing number of insurance plans. Available as a weekly injection and, as of January 2026, a daily oral pill.

Tirzepatide (Zepbound / Mounjaro) is a dual GLP-1 and GIP receptor agonist. By activating two hormone receptors instead of one, it produces approximately 21 percent average weight loss over 72 weeks. Also FDA-approved, available as a weekly injection.

These are not placeholders. They are proven, life-changing medications that have helped hundreds of thousands of people. Everything in the pipeline is building on this foundation — not replacing it.

Coming in 2026: The Oral Revolution

Orforglipron (Eli Lilly)

What it is: A once-daily oral pill that activates the GLP-1 receptor — the same target as semaglutide, but in pill form without the injection.

Why it matters: Orforglipron is a small-molecule nonpeptide GLP-1 agonist. Unlike oral Wegovy, which must be taken first thing in the morning on an empty stomach, orforglipron can be taken at any time of day without food or water restrictions.

The data: In Phase 2 trials, participants lost 9.4 to 14.7 percent of body weight over 36 weeks. Multiple Phase 3 trials have been completed, and Eli Lilly has submitted for regulatory approval. An FDA decision is expected in the first half of 2026.

Who this is for: Patients who want GLP-1 treatment but do not want to inject. Patients who need a simpler dosing routine. Patients for whom cost of injection-based medications is a barrier.

Coming in 2026–2027: The Next Generation Injectables

CagriSema (Novo Nordisk)

What it is: A fixed-dose combination of semaglutide (GLP-1 agonist) and cagrilintide (an amylin analog) in a single weekly injection.

Why it matters: CagriSema adds a second hormonal mechanism — amylin — which appears to help preserve bone mass and lean body mass during weight loss.

The data: In the Phase 3 REDEFINE-1 trial, CagriSema produced 22.7 percent average weight loss at 68 weeks. Novo Nordisk filed for FDA approval in December 2025, with a U.S. launch expected in 2027.

Survodutide (Boehringer Ingelheim / Zealand Pharma)

What it is: A dual agonist targeting GLP-1 and glucagon receptors.

Why it matters: The glucagon receptor promotes fat burning and energy expenditure and has shown particular promise for liver fat reduction.

The data: Phase 2 trial produced 14.9 percent average weight loss over 46 weeks. An FDA decision for the obesity indication could come as early as 2027.

Coming in 2027–2028: The Next Frontier

Retatrutide (Eli Lilly)

The first triple agonist — activating GLP-1, GIP, and glucagon receptors simultaneously. Phase 2: 24.2 percent at 48 weeks. Phase 3 TRIUMPH-4: 28.7 percent at 68 weeks — the highest ever recorded. Potential market availability in 2027 to 2028.

Amycretin (Novo Nordisk)

Dual agonist targeting GLP-1 and amylin receptors. 22 percent average weight loss in just 36 weeks. Oral formulation showed 13 percent weight loss in 16 weeks. Market availability likely 2028 or beyond.

MariTide (Amgen)

Monthly injectable combining GLP-1 agonism with GIP antagonism. Approximately 20 percent at 52 weeks with once-monthly injection schedule. Potential availability in 2028.

The Full Pipeline at a Glance

Weight loss percentages are approximate, based on trial data at various doses and durations. Final labeled results may differ.

What This Means for Your Decision

If you have not started treatment yet: Start now. Semaglutide and tirzepatide are proven, FDA-approved, and available today. Every month on treatment is a month of progress.

If you are on semaglutide and it is working: Stay the course. When CagriSema or other options become available, you and your provider can evaluate whether switching makes sense.

If you have plateaued on semaglutide: Talk to your provider about tirzepatide. The dual mechanism breaks through plateaus for many patients.

If you want an oral option: Oral Wegovy is available now. Orforglipron is expected in 2026 with more flexible dosing.

The worst decision is no decision. The best medication is not the one with the highest trial number — it is the one you can access, afford, and tolerate right now.